SEC Company Response from MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Sep 8, 2017
MetaVia Inc. (MTVA) (CIK 0001638287)
Date: Sept. 8, 2017 · CIK: 0001638287 · Accession: 0001638287-17-000014
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220315
Letter
SEC Acceleration request for S-3 Effectiveness-9-8-17
September 8, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention:Irene Paik
Re:
Gemphire Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-220315
Acceleration Request
Requested Date:
September 12, 2017
Requested Time:
5:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-220315) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes each of Phillip D. Torrence, Meredith Ervine and Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP by telephone at (313) 465-7620.
Sincerely,
Gemphire Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm SEC Acceleration request for S-3 Effectiveness-9-8-17 September 8, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention:Irene Paik Re: Gemphire Therapeutics Inc. Registration Statement on Form S-3 File No. 333-220315 Acceleration Request Requested Date: September 12, 2017 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-220315) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes each of Phillip D. Torrence, Meredith Ervine and Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP, counsel to the Company, to make such request on its behalf. Please confirm the effectiveness of the Registration Statement with Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP by telephone at (313) 465-7620. Sincerely, Gemphire Therapeutics Inc. /s/ Steven Gullans Steven Gullans Interim President and Chief Executive Officer cc: Jeffrey S. Mathiesen, Gemphire Therapeutics Inc. Phillip D. Torrence, Honigman Miller Schwartz and Cohn LLP Meredith Ervine, Honigman Miller Schwartz and Cohn LLP Gabrielle L. Sims, Honigman Miller Schwartz and Cohn LLP